Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016

Int J Cardiol. 2017 Jul 1:238:5-11. doi: 10.1016/j.ijcard.2017.03.155. Epub 2017 Apr 1.

Abstract

Cachexia in the context of heart failure (HF) has been termed cardiac cachexia, and represents a progressive involuntary weight loss. Cachexia is mainly the result of an imbalance in the homeostasis of muscle protein synthesis and degradation due to a lower activity of protein synthesis pathways and an over-activation of protein degradation. In addition, muscle wasting leads to of impaired functional capacity, even after adjusting for clinical relevant variables in patients with HF. However, there is no sufficient therapeutic strategy in muscle wasting in HF patients and very few studies in animal models. Exercise training represents a promising intervention that can prevent or even reverse the process of muscle wasting, and worsening the muscle function and performance in HF with muscle wasting and cachexia. The pathological mechanisms and effective therapeutic approach of cardiac cachexia remain uncertain, because of the difficulty to establish animal cardiac cachexia models, thus novel animal models are warranted. Furthermore, the use of improved animal models will lead to a better understanding of the pathways that modulate muscle wasting and therapeutics of muscle wasting of cardiac cachexia.

Keywords: Cachexia; Chronic heart failure; Exercise training; Muscle performance; Sarcopenia.

Publication types

  • Review

MeSH terms

  • Animals
  • Cachexia / diagnosis
  • Cachexia / physiopathology*
  • Cachexia / therapy
  • Exercise / physiology*
  • Heart Failure / diagnosis
  • Heart Failure / physiopathology*
  • Heart Failure / therapy
  • Humans
  • Muscle, Skeletal / physiopathology*
  • Muscular Atrophy / diagnosis
  • Muscular Atrophy / physiopathology
  • Muscular Atrophy / therapy
  • Sarcopenia / diagnosis
  • Sarcopenia / physiopathology*